Testing effectiveness (Phase 2)Study completedNCT03625388
What this trial is testing
Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Who this might be right for
Chronic Myelogenous Leukemia
Hikma Pharmaceuticals LLC 56